MAP2K7 and cutaneous melanoma: Recently, there have been major advancements in the treatment of cutaneous melanoma, due to the introduction of targeted therapies, including for example vemurafenib and dabrafenib (BRAF kinase inhibitors) and trametinib and cobimetinib (MEK inhibitors) (219–221).